Your session is about to expire
← Back to Search
H2 Receptor Antagonist
Repurposing a Histamine Antagonist to Benefit Patients With Pulmonary Hypertension (REHAB-PH Trial)
Phase 2
Waitlist Available
Led By Peter J Leary, MD, PhD
Research Sponsored by University of Washington
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 24 weeks
Awards & highlights
Approved for 5 Other Conditions
All Individual Drugs Already Approved
Summary
This trial tests famotidine, a common heartburn medication, in adults with pulmonary arterial hypertension. The goal is to see if it can help the right side of the heart become stronger and work better under stress. Participants will take the medication for a period of time and have regular check-ups to monitor their heart function.
Eligible Conditions
- Pulmonary Arterial Hypertension
- Cor Pulmonale
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 24 weeks
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~24 weeks
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Change in Six-minute Walk Distance
Secondary study objectives
Chang in Log-transformed BNP
Change in Health Related Quality of Life (emPHasis-10 Questionnaire)
Change in Right Ventricular Morphology by Echocardiogram (RV Dilation and TAPSE)
+2 moreOther study objectives
Cardiopulmonary Exercise Testing (Sub-study): Exercise
Cardiopulmonary Exercise Testing (Sub-study): Maximal Oxygen Uptake
Invasive Hemodynamics (Sub-study): Hemodynamics
+1 moreSide effects data
From 2023 Phase 2 trial • 80 Patients • NCT0355429120%
Coronavirus, Influenza, Medical Device site infection, Ear infection, Metapneumovirus, Nasopharyngit
20%
Abdominal pain, dyspepsia, nausea, flatulence, discomfort
13%
Syncope, Dizziness, Headache, Dysgeusia, Encephalopathy
10%
dyspnea, hemoptysis, throat irritation
10%
Atrial flutter, Angina Pectoris, Cardiac Failure
10%
angina, atrial flutter, cardiac failure
10%
Coronavirus, Medical Device Site Infection, Metapneumovirus, Pneumonia
8%
syncope, encephalopathy
5%
Acute Kidney Injury
5%
dehydration, hypokalemia
5%
acute kidney injury,
5%
non-cardiac chest pain, swelling
5%
Dyspnea, Hemoptysis
5%
Dehydration, Hypokalemia
3%
hypotension
3%
Hypotension
3%
rash
3%
vaginal hemorrhage
3%
back pain, bursitis, neck pain
100%
80%
60%
40%
20%
0%
Study treatment Arm
Placebo
Famotidine
Awards & Highlights
Approved for 5 Other Conditions
This treatment demonstrated efficacy for 5 other conditions.
All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
Trial Design
2Treatment groups
Experimental Treatment
Placebo Group
Group I: FamotidineExperimental Treatment1 Intervention
20mg of oral famotidine (pill) daily
Other names: Pepcid
Group II: PlaceboPlacebo Group1 Intervention
Daily oral placebo (pill)
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Famotidine
FDA approved
Find a Location
Who is running the clinical trial?
University of WashingtonLead Sponsor
1,831 Previous Clinical Trials
1,907,489 Total Patients Enrolled
1 Trials studying Pulmonary Arterial Hypertension
60 Patients Enrolled for Pulmonary Arterial Hypertension
National Heart, Lung, and Blood Institute (NHLBI)NIH
3,943 Previous Clinical Trials
47,797,813 Total Patients Enrolled
27 Trials studying Pulmonary Arterial Hypertension
3,151 Patients Enrolled for Pulmonary Arterial Hypertension
Peter J Leary, MD, PhDPrincipal InvestigatorUniversity of Washington